• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, November 16, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Adults With MASLD Aged 75 and Older Face Elevated Polypharmacy Rates

by
November 16, 2026
in Health
Reading Time: 6 mins read
0
Adults With MASLD Aged 75 and Older Face Elevated Polypharmacy Rates

Adults With MASLD Aged 75 and Older Face Elevated Polypharmacy Rates

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

In an analysis of nationally representative data from the United States, community-dwelling adults aged 75 years and older with metabolic dysfunction-associated steatotic liver disease experienced significantly higher rates of polypharmacy than their peers without the liver condition. Specifically, 60.3 percent of older individuals with the disease were identified as taking multiple concurrent medications compared to 42.7 percent of their counterparts without the diagnosis, representing a statistically significant difference documented by investigators examining nationwide survey records. This central observation emerged from an investigation conducted by Wang and colleagues published in the Journal of General Internal Medicine, which evaluated medication regimens among older adults to characterize how the presence of hepatic steatosis intersects with prescribing patterns in aging populations. Across younger cohorts of older adults evaluated in the same study, polypharmacy rates were observed to rise with advancing age but remained comparable between individuals with and without the liver condition. The notable divergence documented among adults aged 75 and older highlights a distinct prescribing landscape for the oldest segment of patients living with this metabolic liver disorder.

Metabolic dysfunction-associated steatotic liver disease, clinically defined by hepatic steatosis exceeding 5 percent on diagnostic imaging or tissue biopsy in the simultaneous presence of at least one cardiometabolic risk factor, represents an expanding contributor to the nationwide burden of chronic illness. Epidemiological forecasts indicate that rates of this liver condition are projected to triple among American adults aged 80 years and older in the coming decades, concentrating disease prevalence within an age demographic that is already vulnerable to adverse medication events. While federal regulatory agencies have approved very few medical therapies specifically indicated for metabolic dysfunction-associated steatotic liver disease itself when it occurs in the absence of metabolic dysfunction-associated steatohepatitis, the underlying disorder frequently coexists with multiple cardiometabolic conditions. Because these co-occurring chronic diseases routinely require pharmacologic intervention, clinicians frequently face the delicate task of balancing complex therapeutic trade-offs, navigating treatment risks alongside potential clinical benefits, and engaging older patients in shared decision-making despite historical uncertainty surrounding the exact epidemiological prevalence of concurrent medication use in this population.

To clarify this prescribing landscape, Wang and colleagues examined a nationally representative cross-section of community-dwelling older adults aged 65 years and older utilizing data collected through the 2017 to 2020 cycles of the National Health and Nutrition Examination Survey. The researchers identified study participants with metabolic dysfunction-associated steatotic liver disease by applying image-guided measurements to quantify hepatic steatosis in combination with examination findings or medication-derived indicators of cardiometabolic risk factors. Rather than relying solely on electronic administrative coding or unverified diagnostic claims databases, the research protocol systematically assessed active medication use through direct participant self-reporting combined with a structured, in-person physical review of prescription pill bottles brought by participants. By leveraging the standardized sampling structure of the National Health and Nutrition Examination Survey, the study established a vital population-based comparator group of individuals without the liver condition, thereby providing empirical generalizability that extends beyond earlier published cohorts that depended predominantly on specialized clinical registries and selective institutional patient databases.

In their primary analytical framework, the authors implemented multivariable regression models adjusted for selected demographic characteristics, advanced liver fibrosis, and specific cardiometabolic comorbidities to isolate the relationship between liver disease and medication burden. These adjusted models confirmed that while the proportion of individuals taking multiple concurrent medications increased progressively as participants grew older, polypharmacy rates were largely indistinguishable between individuals with and without metabolic dysfunction-associated steatotic liver disease across most examined age brackets. It was only upon evaluating individuals aged 75 years and older that a marked and statistically significant disparity materialized, with polypharmacy affecting 60.3 percent of participants with the liver condition versus 42.7 percent among peers without the disorder, yielding a probability value below 0.01. This statistical pattern demonstrates that the substantial divergence in polypharmacy is not uniform across all older adults with the condition, but instead emerges predominantly among the oldest individuals evaluated in the nationwide cohort.

The methodological design of the investigation provides several substantive strengths for understanding geriatric medication use, most prominent among them being the strategic employment of a nationally representative epidemiological survey. Prior scientific literature addressing pharmacotherapy in metabolic liver disease frequently depended on specialized disease registries, which can introduce notable selection biases and limit the degree to which observational findings can be extrapolated to community-dwelling older populations. In contrast, the current dataset permitted direct, structured comparisons between older adults diagnosed with metabolic dysfunction-associated steatotic liver disease and individuals exhibiting similar demographic characteristics who do not have the condition. This comparative methodology directly advances ongoing scholarly inquiry regarding whether older patients diagnosed with metabolic steatosis exhibit an entirely distinct medication-regimen phenotype compared with older adults more broadly, or whether their observed prescribing profiles fundamentally mirror the general medication patterns observed across the aging population as chronic disease accumulation accelerates.

Despite the clear headline finding showing elevated medication counts among adults aged 75 and older, a meticulous evaluation of the underlying data reveals complex clinical questions regarding whether these patients are experiencing overprescribing, undertreatment, or clinically appropriate management across their lifespans. Within the study sample, individuals diagnosed with metabolic dysfunction-associated steatotic liver disease presented with a greater cumulative burden of cardiometabolic conditions compared to their peers without the liver diagnosis. Nonetheless, across the majority of evaluated age categories, patients with the liver disease were recorded as utilizing approximately the same absolute number of cardiometabolic medications as those without the disorder. This striking parity in drug counts, occurring in the face of a higher underlying disease prevalence, suggests the possibility of systemic undertreatment among a patient cohort recognized to possess elevated cardiovascular risk profiles that might otherwise warrant more intensive guideline-directed pharmacologic therapies to mitigate vascular risk.

A contrasting interpretive perspective arises when scrutinizing the specific therapeutic classes prescribed to the oldest participants in the survey cohort. Among community-dwelling adults aged 75 years and older, individuals diagnosed with metabolic dysfunction-associated steatotic liver disease received a significantly greater number of prescriptions specifically for antihypertensive and antidiabetic agents than their counterparts without liver involvement, aligning with their higher burden of cardiometabolic disease. Because these older patients demonstrated a documented excess of cardiometabolic comorbidities, the higher frequency of these targeted cardiovascular and metabolic prescriptions may represent clinically appropriate medical care rather than indiscriminate or hazardous polypharmacy. This appropriate-treatment interpretation is reinforced by the observation that the absolute difference in the total number of medications used between older adults with and without the condition remained under one single prescription, while multivariable modeling did not incorporate several cardiovascular comorbidities that correlate both with polypharmacy and liver steatosis. Furthermore, rates of hyperpolypharmacy and the utilization of sedating medications showed no significant differences between individuals with and without the liver disease in this oldest age group.

Disentangling whether an elevated prescription count represents judicious clinical management or unnecessary therapeutic risk remains an enduring dilemma for pharmacoepidemiologists and clinical investigators studying deprescribing interventions. Although numerous randomized clinical trials have successfully demonstrated that older adults can be safely guided to discontinue high-risk medications, there remains very limited empirical evidence showing that reducing overall pill counts directly improves hard clinical outcomes or patient-reported satisfaction, even when discontinuation efforts specifically target potentially inappropriate drugs. Because broad, population-wide campaigns aimed at lowering prescription numbers have not consistently translated into measurable clinical benefits, researchers have proposed shifting targeted deprescribing strategies toward specific patient populations defined by vulnerability. These targeted groups could include individuals living with clinical conditions that impair medication metabolism or increase susceptibility to frailty, such as metabolic dysfunction-associated steatotic liver disease, or severely frail individuals whose chronic diseases are already controlled beyond established guideline targets. Consequently, future epidemiologic investigations are necessary to evaluate clinical outcomes across varying amounts of medication use to determine whether this population would genuinely benefit from bespoke deprescribing interventions.

The clinical heterogeneity inherent to older adults further complicates blanket prescribing policies, because polypharmacy and potentially hazardous medication regimens present distinctly variable risk profiles from one patient to another. Reducing medication regimens among older adults who share the same diagnostic label, even a diagnosis linked to heightened vulnerability to adverse drug events, may still fail to demonstrate measurable health improvements on average, even if isolated individuals derive meaningful protection. This dynamic mirrors established principles in preventive medicine, such as the routine prescription of statins for primary cardiovascular prevention: while the majority of individual patients prescribed a statin will not personally avert a myocardial infarction or stroke, the therapy is widely prescribed because it provides clear benefits on a population average with minimal risk of serious harm. For medication deprescribing, however, this average balance between therapeutic benefit and potential withdrawal harm has not been definitively established, underscoring the urgent necessity for refined precision methodologies.

Moving beyond blunt clinical proxies such as chronological age and generalized frailty marks a crucial step toward optimizing pharmacotherapy through individualized precision medicine, an approach that has already transformed oncology and advanced aspects of cardiology. While identifying patient cohorts with high polypharmacy rates, such as older adults with metabolic dysfunction-associated steatotic liver disease, serves as an essential preliminary milestone, clinical practice requires tools capable of translating subgroup epidemiology into personalized probability estimates of marginal benefit and harm. Whereas clinical trials often struggle with statistical power to detect treatment heterogeneity and administrative records frequently lack efficacy measures, safety outcomes such as severe gastrointestinal bleeding, acute kidney injury, and serious falls are reliably documented in existing large observational databases. Rather than withholding medications based on age alone, future precision pharmacoepidemiology could leverage these large data sources to quantify an individual patient’s specific marginal risk. By applying personalized risk modeling to safety endpoints, clinicians and patients can transition from blunt population estimates to informed conversations, ensuring therapies are deprescribed when verified individual risks demonstrably outweigh benefits, while preserving essential treatments that maintain cardiovascular and metabolic stability.

Subject of Research: Polypharmacy and deprescribing considerations in older adults with metabolic dysfunction-associated steatotic liver disease

Article Title: Beyond the Prescription Count: MASLD, Polypharmacy, and Moving to More Precise Deprescribing

Article References: Lee, D., & Chaitoff, A. (2026). Beyond the Prescription Count: MASLD, Polypharmacy, and Moving to More Precise Deprescribing. Journal of General Internal Medicine. https://doi.org/10.1007/s11606-026-10755-2

Image Credits: AI Generated

DOI: 10.1007/s11606-026-10755-2

Keywords: MASLD, polypharmacy, deprescribing, NHANES, older adults, hepatic steatosis, cardiometabolic risk, geriatric medicine, antihypertensive medications, antidiabetic prescriptions, hyperpolypharmacy, precision medicine, pharmacoepidemiology, treatment heterogeneity, shared decision-making, medication safety

News Source: Ophelia Keating. (November 16, 2026). Adults With MASLD Aged 75 and Older Face Elevated Polypharmacy Rates. Scienmag.

Tags: antidiabetic prescriptionsantihypertensive medicationscardiometabolic riskdeprescribingGeriatric medicinehepatic steatosishyperpolypharmacyMASLDMedication safetyNHANESolder adultspharmacoepidemiologypolypharmacyPrecision Medicineshared decision-makingTreatment heterogeneity
Share12Tweet7Share2ShareShareShare1

Related Posts

Systematic Review Evaluates Machine Learning Methods for Automated Diabetic Retinopathy Detection

Systematic Review Evaluates Machine Learning Methods for Automated Diabetic Retinopathy Detection

November 16, 2026
Global Corpus Uteri Cancer Cases Projected to Reach 676,296 by 2050

Global Corpus Uteri Cancer Cases Projected to Reach 676,296 by 2050

November 16, 2026

Study Finds Conserved Pattern of Probiotic Absence in Individuals With Autism

November 16, 2026

Comprehensive Review Details How Cancer Hijacks Chemical Structural and Electrical Neural Circuits

November 16, 2026

POPULAR NEWS

  • Review Assesses Biochar Membranes as Sustainable Candidates for Industrial Carbon Dioxide Capture

    Review Assesses Biochar Membranes as Sustainable Candidates for Industrial Carbon Dioxide Capture

    29 shares
    Share 12 Tweet 7
  • Stacking Machine Learning Model Detects Toddler Autism Signs With Ninety-Nine Percent Accuracy

    29 shares
    Share 12 Tweet 7
  • Engineered Statistical Features Drive Network Anomaly Detection Over Complex Deep Architectures

    29 shares
    Share 12 Tweet 7
  • Integrated Camera and Laser Mapping Enables Automated 3D Tunnel Defect Inspection

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Biochar Reshapes Rhizosphere Microenvironments and Boosts Root Nutrient Retention

Systematic Review Evaluates Machine Learning Methods for Automated Diabetic Retinopathy Detection

Green Spectrophotometric Assay Accurately Measures Dual Antibiotic Pill Without Chemical Separation

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 87 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.